ISRIB

ISRIB is an experimental small molecule discussed for clearer thinking, reduced mental friction and recovery from prolonged stress or brain injury. Personal accounts range from striking subjective change to mild, uncertain benefit or no relief. Some recovery stories concern the related compound ISRIB-A15, so the name and form matter before comparing experiences.

What it is and why people discuss it

• A research small molecule aimed at a cellular stress response. ISRIB stands for integrated stress response inhibitor. It acts through eIF2B, part of the machinery that starts protein production; the idea is to relieve a cellular brake on that production. Cellular stress is broader than feeling anxious or burned out. Animal context
• Memory headlines meet personal recovery hopes. Nootropic discussions center on clearer thinking, less mental friction and recovery after injury or prolonged stress. Longevity interest draws on memory findings in old mice, which do not demonstrate human rejuvenation or longer life. Personal report Personal report Animal context
• Trans-ISRIB and ISRIB-A15 should stay distinct. The primary research calls trans-ISRIB “ISRIB-A1”; cis-ISRIB is a different stereoisomer. A15 is a chemically modified analog, not another spelling or delivery form, so its experiences cannot fill gaps in the parent compound’s dose or effects. Animal context

Benefits people report

• Less hesitation and rumination. One 2026 user described easier task initiation, less social anxiety and more natural appetite after classic ISRIB. This was a subjective first-day account after burnout, with other supplements already in use. Personal report
• A favorable report later described as subtle. Luminary first reported a good response compared with other nootropics, then clarified that any effect might be subtle and was not felt immediately. The follow-up qualifies the initial enthusiasm. Rapamycin News
• Mild change or no useful change. A 2021 log eventually questioned whether modest stress relief was placebo. A separate poster with post-orgasmic illness symptoms listed ISRIB among unsuccessful attempts to relieve persistent brain fog and fatigue. Neither account supplies a response rate. Personal report Personal report
• A15: sleep and energy claims with remaining difficulties. One commenter with a reported childhood brain injury described better sleep and more desire to be active, while focus, task management and working memory remained troublesome. That is an analog account with incomplete recovery, not proof of parent ISRIB repairing a brain. Personal report

Doses people discuss

• 15 mg orally: one classic-ISRIB first-day report. The author later said they were moving to 30 mg; that statement does not verify subsequent dosing or how much was absorbed. It is an individual report, not a common-dose band. Personal report
• 10 mg toward 20 mg: inconsistent trans-ISRIB use. Luminary described swallowing a DMSO-containing preparation, without a clear frequency. The account does not establish a daily total or an equivalent amount for another formulation. Rapamycin News
• 20–30 mg orally three times daily: a separate, uncertain-product log. The 2021 author later tried 50 mg twice daily, then 25 mg twice daily, with little added benefit. Daily totals are 60–90 mg, 100 mg and 50 mg respectively; disputed product identity prevents treating these as authenticated trans-ISRIB exposure. Personal report

Half-life

• About eight hours is a circulated preclinical claim. Rapamycin News attributes this figure to preclinical research, and an older Phoenix Rising summary explicitly says mice. It is not a measured human oral half-life; felt effects cannot establish clearance. Rapamycin News Phoenix Rising

Onset: when people notice a change

• Hours, later in the day, or nothing immediate. The 2026 classic-ISRIB author described changes within hours. The 2021 log noticed mild effects later in the day after repeated amounts, while Luminary reported no immediate feeling. None provides a reliable onset clock for another person. Personal report Personal report Rapamycin News

Duration: how long a change lasts

• No dependable one-dose benefit window. The 2021 author thought mild improvement might persist a week after stopping but questioned placebo. Repeated dosing prevents isolating a single amount’s duration. Personal report
• A15 benefits partly faded during the following week. The A15 commenter described some sleep gains wearing off and partial rollback of perceived improvement. This does not show that parent ISRIB lasts a week, or that either compound produces permanent repair. Personal report

Cycles and time off

• Three days planned, five days later reported. The 2026 author initially described three consecutive days, then reported a five-day course in the crosspost. The first dose felt strongest, with little added change afterward; these posts are one person’s evolving account. Personal report
• Breaks are improvised, not validated washouts. The 2021 log included a roughly week-long pause before restarting. The A15 commenter explicitly called weekly spacing an educated guess. These accounts establish neither an optimal course nor protection from repeated-use risks. Personal report Personal report

Good to know

• Fatigue and sleepiness can accompany the interest. A responder to the 2026 post reported fatigue at higher amounts but did not fully specify form or route. The separate A15 commenter reported sleepiness above 5 mg; that threshold belongs to that person and analog. Personal report Personal report
• Serious adverse stories are secondhand and unverified. A Phoenix Rising post relays collapse with a reported arrhythmia after nasal use, chest discomfort after mixed nasal/oral use, and hallucinations with psychosis in someone with prior episodes. Original records were not inspected; these are unresolved warning reports, not confirmed causation or an incidence estimate. Phoenix Rising
• Delivery claims are unusually uncertain. Posts disagree about absorption and contain confident percentages without human measurements. A powder’s labeled milligrams do not tell the reader the absorbed dose, and a lack of effect does not justify assuming that more powder or a different route would solve it. Personal report Personal report
• Changing a cell-defense pathway has unanswered consequences. The integrated stress response helps cells respond to adverse conditions. Laboratory evidence that ISRIB can alter it does not define human long-term safety, interactions or a safe exposure; a forum report of no side effects is too narrow to settle those questions. Animal context
• A research label does not authenticate the contents. The 2021 discussion disputed whether the supplied material matched its stereoisomer label. That uncertainty limits interpretation of both positive and negative reports, without proving that any particular product was mislabeled. Personal report

From community discussion

• Feeling less inhibited is not a memory test. The first-day author’s appealing account concerned willingness to act and reduced rumination. Changes in social confidence, appetite or motivation do not establish improved learning, an IQ increase or tissue repair. Personal report
• Persistent symptoms despite trying several nootropics. The post-orgasmic illness account listed ISRIB, Semax, Selank and Cerebrolysin among compounds that had not relieved the author’s symptoms. Amounts, forms and whether use overlapped were unstated, so it cannot rank those compounds or isolate an interaction. Personal report
• Brain fog and emotional blunting are also reported. The Phoenix Rising summary also relays increased brain fog and blunted emotions. It repeats a claim that food relieved the fog, but that is an unverified observation, not an established explanation or remedy. Phoenix Rising
• Other compounds blur attribution. A commenter in the 2026 thread mentioned combining ISRIB with dihexa or mushrooms. Such co-use is a reason to keep attribution uncertain, not evidence that companions are required or that the combinations are safe. Personal report
• ISRIB and Dihexa answer different comparison questions. Dihexa appears as a companion in one account, but no inspected report directly compared the two under controlled conditions. For ISRIB itself, the first useful distinction is parent versus A15; their amounts and outcomes cannot be pooled. Personal report Animal context

Related human research

• A trial of a related compound is not an ISRIB trial. DNL343 also activates eIF2B, but it is a different molecule. Its randomized ALS trial, published in September 2026, found no slowing of disease progression; that result neither validates parent ISRIB self-experimentation nor directly tests its claimed nootropic effects. Official context